Profile - To The Moon

SSKONG

Posts · 1Posts · 1
Following · 0Following · 0
Followers · 0Followers · 0

- SSKONGSSKONG
  ·2021-09-08
  Great ariticle, would you like to share it?
  Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B
  (Update: Sept 8, 2021 at 04:13 a.m. ET) With an aim to further strengthen growth of transplant busin
  Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B
  93 Comment
  1
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583495200359485","uuid":"3583495200359485","gmtCreate":1620401175936,"gmtModify":1620401175936,"name":"SSKONG","pinyin":"sskong","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":1,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":889018183,"gmtCreate":1631090626842,"gmtModify":1676530464940,"author":{"id":"3583495200359485","authorId":"3583495200359485","name":"SSKONG","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3583495200359485","idStr":"3583495200359485"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889018183","repostId":"1152225600","repostType":4,"repost":{"id":"1152225600","kind":"news","pubTimestamp":1631087910,"share":"https://ttm.financial/m/news/1152225600?lang=&edition=fundamental","pubTime":"2021-09-08 15:58","market":"us","language":"en","title":"Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B","url":"https://stock-news.laohu8.com/highlight/detail?id=1152225600","media":"seekingalpha","summary":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant busin","content":"<p><i><b>(Update: Sept 8, 2021 at 04:13 a.m. ET)</b></i></p>\n<p>With an aim to&nbsp;further strengthen growth of transplant business,&nbsp;<b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b> will&nbsp;acquire<b>&nbsp;<a href=\"https://laohu8.com/S/KDMN\">Kadmon</a></b> Holdings&nbsp;total equity value of ~$1.9B.</p>\n<p>Following completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the&nbsp;shareholders of Kadmon common stock will receive $9.50/share in cash.</p>\n<p>The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.</p>\n<p>Rezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.</p>\n<p>Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.</p>\n<p>The transaction is expected to be completed in Q4 2021.</p>\n<p>Sanofi has upped its mRNA game with recent acquisitions of&nbsp;Translate Bio for $3.2BandTidal Therapeutics for $470M.</p>\n<p>Also, to bolster its presence in&nbsp;immunology, SNYacquired&nbsp;Kymab for $1.45B in January 2021.</p>\n<p>Kadmon surged over 70% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f86d88920aa0b1f514e5ea60e5515774\" tg-width=\"976\" tg-height=\"566\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/2a32c99fe7d6a680a8d65ac1cbb1f616\" tg-width=\"964\" tg-height=\"572\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi strengthens transplant business with acquisition of Kadmon for $1.9B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KDMN":"Kadmon Holdings LLC","SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1152225600","content_text":"(Update: Sept 8, 2021 at 04:13 a.m. ET)\nWith an aim to further strengthen growth of transplant business, Sanofi SA will acquire Kadmon Holdings total equity value of ~$1.9B.\nFollowing completion of the merger, a wholly owned subsidiary of Sanofi will merge with Kadmon and the shareholders of Kadmon common stock will receive $9.50/share in cash.\nThe acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock (belumosudil) to its transplant portfolio.\nRezurock is a recently FDA-approved treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.\nKadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.\nThe transaction is expected to be completed in Q4 2021.\nSanofi has upped its mRNA game with recent acquisitions of Translate Bio for $3.2BandTidal Therapeutics for $470M.\nAlso, to bolster its presence in immunology, SNYacquired Kymab for $1.45B in January 2021.\nKadmon surged over 70% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}